Clinic and semiotics of digestive lesions with coronavirus SARS-CoV-2
https://doi.org/10.31146/1682-8658-ecg-186-2-20-26
Abstract
The article presents the results of the analysis of clinical features of gastroenterological manifestations of a new coronavirus infection (COVID-19) caused by the pathogen SARS-CoV-2. Taking into account the stage-by-stage system assessment of the experience of treating 1,180 patients in a multi-specialty hospital transformed into an infectious hospital, the most characteristic clinical manifestations of digestive damage by SARS-CoV-2 coronavirus are described. The article focuses on verification of changes in the digestive system, both at the stage of primary examination, and during etiotropic (in combination with hydroxychloroquine and azithromycin, interferon-alpha drugs), pathogenetic (in combination with corticosteroids, heparin drugs, according to indications - an interleukin-6 inhibitor) and symptomatic (antipyretics, antiemetics and antitussive drugs) therapy, carried out in accordance with Temporary guidelines of the Ministry of health of the Russian Federation “Prevention, diagnosis and treatment of new coronavirus infection Covid-19”. Directions for the development of algorithms for clinical and laboratory, instrumental and radiological diagnostics of changes in the digestive system in patients with COVID-19 are justified.
About the Authors
N. G. Kucherenko
FGBU “Northwest District Research and Clinical Center by L. G. Sokolov FMBA of Russia”
Russian Federation
Russian Federation
A. K. Ratnikova
FGBU “Northwest District Research and Clinical Center by L. G. Sokolov FMBA of Russia”; Military Medical Academy named after S. M. Kirov
Russian Federation
Russian Federation
V. B. Grinevich
Military Medical Academy named after S. M. Kirov
Russian Federation
Russian Federation
E. I. Tkachenko
Military Medical Academy named after S. M. Kirov
Russian Federation
Russian Federation
Yu. A. Kravchuk
Military Medical Academy named after S. M. Kirov
Russian Federation
Russian Federation
References
1. Cha M.H., Regueiro M., Sandhu D. S. Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. World J. Gastroenterol. 2020; 26 (19): 2323-2332.
2. Temporary guidelines of the Ministry of Health of the Russian Federation. Prevention, diagnosis and treatmentof new coronavirus infection (COVID-19). Moscow. Version 10 (08/02/2021), 261 p.
3. Cavalli G., De Luca G., Campochiaro C. et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020; 2(6): e325-e331.
4. Rapid Expert Consultations on the COVID-19 Pandemic: March 14, 2020-April 8, 2020 National Academies of sciences, engineering, and medicine Washington (DC): National Academies Press (US); 2020 Apr 30.
5. Mao R., Qiu Y., He J-S., et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2020: S2468-1253(20)30126-6.
6. Ivashkin V.T., Sheptulin A. A., Zolnikova O. Yu. et al. New coronavirus infection (COVID-19) and digestive system. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020; 30(3): 7-13. (In Russ.) https://doi.org/10.22416/1382-4376-2020-30-3-7
7. Grinevich V.B., Gubonina I. V., Doshchitsin V. L. et al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention. 2020; 19 (4): 2630. (In Russ.) https://doi.org/10.15829/1728-8800-2020-2630
8. Grinevich V.B., KravchukYu.A., Ped V. I. et al. Management of patients with digestive diseases during the COVID-19 pandemic: clinical practice guidelines by the Gastroenterological scientific society of Russia. Experimental and Clinical Gastroenterology. 2020; (7): 4-51. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-179-7-4-51
9. Klyushin D. A., Petunin Yu. I. Evidence-based medicine. Application of statistical methods. Moscow. LLC “I. D. Williams” Publ., 2017, 316 p.@@ Клюшин Д.А., Петунин Ю. И. Доказательная медицина. Применение статистических методов. - М.: ООО «И. Д. Вильямс», 2017-316 с.
10. Cascella M., RajnikM., CuomoA. et al. Features, evaluation and treatment of coronavirus (COVID-19). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020.
11. Ma C., Cong Y., Zhang H. COVID-19 and the digestive system. Am. J. Gastroenterol. 2020: 00:1-4.
12. Xiao F., Tang M., Zheng X. et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020; 158: 1831-1833.
13. Tariq R., Saha S., Furqan F. et al. Prevalence and mortality of COVID-19 patients with gastrointestinal symptoms: a systematic review and meta-analysis. Mayo Clin Proc. 2020; 95(8): 1632-1648. doi:10.1016/j.mayocp.2020.06.003
14. Li M.Y., Li L., Zhang Y., Wang X. S. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect. Dis. Poverty. 2020; 28: 9 (1): 45.
15. Hoffmann M., Kleine-Weber H., Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 16: 181 (2): 271-280.
16. Parasa S., Desai M., Thoguluva Chandrasekar V. et al. Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: A systematic review and meta-analysis. JAMA Netw. Open. 2020; 3(6): e2011335.
17. Zhang C., Shi L., Wang F.-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol. Hepatol. 2020; 5(5): 428-430.
18. Scaldaferri F., Ianiro G., Privitera G. et al. The thrilling journey of SARS-CoV-2 into the intestine: from pathogenesis to future clinical implications. Inflamm. Bowel Dis. 2020; 26 (9): 1306-1314. doi: 10.1093/ibd/izaa181. PMID: 32720978; PMCID: PMC7454647.
19. Hui D.S.C., Zumla A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect. Dis. Clin. North Am. 2019; 33(4): 869-889.
20. Clark A., Jit M., Warren-Gash C. et al. Centre for the Mathematical Modelling of Infectious Diseases COVID-19 working group. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob. Health. 2020; 8(8): e1003-e1017.
21. Bimonte S., Crispo A., Amore A. et al. Potential antiviral drugs for SARS-Cov-2 treatment: preclinical findings and ongoing clinical research. In Vivo. 2020; 34 (3 Suppl): 1597-1602.
22. Anand S., Mande S. S. Diet, microbiota and gut-lung connection. Front. Microbiol. 2018; 9: 2147.
23. Ahlawat S.A., Sharma K. K. Immunological co-ordination between gut and lungs in SARS-CoV-2 infection. Virus Res. 2020; 286: 198103. doi:10.1016/j.virusres.2020.198103.
Review
For citations:
Kucherenko N.G., Ratnikova A.K., Grinevich V.B., Tkachenko E.I., Kravchuk Yu.A. Clinic and semiotics of digestive lesions with coronavirus SARS-CoV-2. Experimental and Clinical Gastroenterology. 2021;(2):20-26. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-186-2-20-26
Views:
592
Email this article 